Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

MRKR

Marker Therapeutics Inc

Jan 17 • 04:00PM ET

2.46

Dollar change -0.20
Percentage change -7.52	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX IOVA ALLO ADAP KPTI CARA AGEN MGNX CERS TXMD

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	28.39%	Shs Outstand	8.90M	Perf Week	-13.07%
Market Cap	26.34M	Forward P/E	-	EPS next Y	-2.19	Insider Trans	22.85%	Shs Float	7.67M	Perf Month	-40.44%
Income	-9.63M	PEG	-	EPS next Q	-0.28	Inst Own	8.95%	Short Float	1.44%	Perf Quarter	-30.11%
Sales	5.40M	P/S	4.88	EPS this Y	-11.70%	Inst Trans	97.27%	Short Ratio	1.98	Perf Half Y	-55.35%
Book/sh	0.84	P/B	2.94	EPS next Y	-108.57%	ROA	-63.39%	Short Interest	0.11M	Perf Year	-43.19%
Cash/sh	0.84	P/C	2.93	EPS next 5Y	-	ROE	-79.76%	52W Range	2.44 - 5.99	Perf YTD	-20.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	52.24%	ROI	-129.32%	52W High	-58.93%	Beta	1.48
Dividend TTM	-	Quick Ratio	3.15	Sales past 5Y	115.54%	Gross Margin	-	52W Low	0.91%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	3.15	EPS Y/Y TTM	48.02%	Oper. Margin	-188.94%	RSI (14)	35.15	Volatility	9.02% 11.68%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-40.47%	Profit Margin	-178.54%	Recom	1.00	Target Price	19.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	23.44%	Payout	-	Rel Volume	0.87	Prev Close	2.66
Sales Surprise	92.60%	EPS Surprise	33.33%	Sales Q/Q	647.66%	Earnings	Nov 14 AMC	Avg Volume	55.80K	Price	2.46
SMA20	-21.99%	SMA50	-28.61%	SMA200	-36.09%	Trades		Volume	48,739	Change	-7.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-21	Initiated	Piper Sandler	Overweight	$6
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight	$6
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $2.50
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

Dec-19-24 08:06AM	Marker Therapeutics Announces $16.1 Million Private Placement (GlobeNewswire) -7.44%
08:05AM	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma (GlobeNewswire)
Dec-17-24 07:00AM	Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer (GlobeNewswire) +17.68%
Dec-10-24 08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann and Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
11:00AM	Loading…
Nov-26-24 11:00AM	Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit (GlobeNewswire)
Nov-14-24 04:30PM	Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -12.29%
Oct-22-24 08:20AM	Marker Therapeutics price target raised to $19 from $11 at Ladenburg (TipRanks) +22.70%
Sep-26-24 02:33PM	AML cell therapy trials to watch in 2024 targeting GvHD (Clinical Trials Arena) +6.59%
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-14-24 04:30PM	Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -5.41%
Aug-12-24 07:00AM	Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma (GlobeNewswire)
Jun-28-24 11:52AM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.42%
May-15-24 11:53PM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:15PM	Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Loading…
Apr-08-24 07:00AM	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies (GlobeNewswire)
Mar-25-24 05:45PM	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results (GlobeNewswire) -10.74%
Mar-22-24 12:30PM	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.82%
Jan-22-24 07:30AM	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601 (GlobeNewswire) +5.56%
Jan-08-24 09:31AM	Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization (Benzinga)
08:24AM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization (GlobeNewswire)
Dec-21-23 11:00AM	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-11-23 07:00AM	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse (GlobeNewswire) +46.85%
Nov-09-23 05:00PM	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.56%
Sep-11-23 07:00AM	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse (GlobeNewswire) +11.41%
Aug-30-23 08:00AM	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +6.75%
Aug-25-23 12:07PM	Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) -5.52%
Aug-17-23 09:03AM	Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies (Newsfile)
Aug-14-23 04:30PM	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +25.75%
Aug-07-23 07:00AM	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program (GlobeNewswire)
07:00AM	Loading…
Jul-26-23 07:00AM	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 (GlobeNewswire)
Jul-22-23 08:12AM	Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95% (Simply Wall St.)
Jul-10-23 07:00AM	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients (GlobeNewswire) +23.04%
Jun-26-23 07:00AM	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration (GlobeNewswire) -6.59%
Jun-12-23 07:00AM	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial (GlobeNewswire) +19.52%
May-31-23 06:30AM	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells (GlobeNewswire) +33.84%
May-17-23 06:11AM	Marker Therapeutics First Quarter 2023 Earnings: US$0.57 loss per share (vs US$1.19 loss in 1Q 2022) (Simply Wall St.)
May-08-23 07:30AM	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer (GlobeNewswire) +15.97%
May-01-23 07:30AM	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady (GlobeNewswire) +16.47%
Mar-22-23 08:10AM	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results (GlobeNewswire) -31.82%
Dec-13-22 07:23PM	Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund (American City Business Journals)
07:00AM	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million (GlobeNewswire)
Nov-22-22 07:28AM	Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely (Simply Wall St.)
07:00AM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Nov-10-22 05:35PM	MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Marker Therapeutics Reports Q3 2022 Operating and Financial Results (GlobeNewswire)
Sep-13-22 07:00AM	Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Markers Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML (GlobeNewswire) +7.12%
Sep-08-22 07:00AM	Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire) +31.50%
Aug-11-22 04:22PM	Marker Therapeutics Reports Q2 2022 Operating and Financial Results (GlobeNewswire) -8.08% -12.24%
Aug-04-22 04:37PM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma (GlobeNewswire) +63.64%
Jun-15-22 07:06AM	Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky (Simply Wall St.)
May-13-22 07:00AM	Marker Therapeutics Reports Q1 2022 Operating and Financial Results (GlobeNewswire)
May-04-22 10:30AM	Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting (GlobeNewswire) +8.00%
Apr-26-22 07:00AM	Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf (GlobeNewswire)
Mar-17-22 05:45PM	Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-07-22 04:05PM	Marker Therapeutics to Present at Two Upcoming March Investor Conferences (GlobeNewswire) +8.86%
Feb-17-22 01:08PM	Why Are Marker Therapeutics Shares Trading Lower On Thursday? (Benzinga) -25.99%
Feb-16-22 04:30PM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion (GlobeNewswire)
Feb-08-22 04:05PM	Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 (GlobeNewswire)
Jan-20-22 06:38AM	Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer (Benzinga) -10.67%
Jan-19-22 04:49PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer (GlobeNewswire)
Jan-06-22 08:53AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.) -5.51%
Dec-31-21 09:40AM	Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock? (Zacks)
Dec-09-21 07:00AM	Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors (PR Newswire)
Nov-18-21 04:05PM	Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting (PR Newswire) -7.35%
Nov-10-21 04:05PM	Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results (PR Newswire)
Oct-08-21 09:24AM	Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR) (Simply Wall St.)
Sep-07-21 04:05PM	Marker Therapeutics to Present at Three Upcoming September Investor Conferences (PR Newswire)
Aug-20-21 12:00PM	38 Stocks Moving In Friday's Mid-Day Session (Benzinga) +8.33%
Aug-19-21 04:05PM	Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas (PR Newswire) -5.08%
Aug-10-21 04:01PM	Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results (PR Newswire)
Aug-09-21 06:57AM	Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-28-21 04:05PM	Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility (PR Newswire)
Jul-06-21 07:00AM	Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML (PR Newswire)
Jun-29-21 09:01AM	Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock? (Insider Monkey)
Jun-16-21 04:05PM	Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference (PR Newswire)
May-20-21 04:06AM	Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation (Simply Wall St.) +5.44%
May-12-21 04:05PM	Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results (PR Newswire) -8.47%
02:45PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Apr-29-21 04:05PM	Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 (PR Newswire)
Apr-27-21 07:41PM	Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (PR Newswire) +8.91%
Apr-08-21 03:23PM	Study shows wearables could detect COVID-19 earlier (Yahoo Finance Video) +6.31%
Apr-07-21 08:32AM	Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't? (Zacks) -8.85%
Mar-16-21 04:57PM	Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock (PR Newswire)
Mar-15-21 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Mar-12-21 08:00AM	Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire) -23.32%
Mar-11-21 04:10PM	Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
Mar-09-21 04:12PM	Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results (PR Newswire) +6.81%
Mar-03-21 07:00AM	Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant (PR Newswire)
Mar-01-21 05:03AM	What Type Of Shareholders Make Up Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Share Registry? (Simply Wall St.) +5.79%
Jan-13-21 07:00AM	Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates (PR Newswire) +8.33%
Jan-05-21 07:00AM	Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial (PR Newswire) +17.69%
Nov-30-20 02:30AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-09-20 04:01PM	Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results (PR Newswire)
03:15PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Nov-02-20 07:00AM	Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020 (PR Newswire)
Sep-17-20 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (PR Newswire)
Aug-10-20 04:00PM	Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results (PR Newswire) -9.81%
Jun-30-20 07:00AM	Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates (PR Newswire)
Jun-23-20 07:00AM	Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia (PR Newswire)

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELMS STEVE	Director	Dec 23 '24	Buy	3.20	11,085	35,472	325,370	Dec 26 04:01 PM
New Enterprise Associates 16,	10% Owner	Dec 23 '24	Buy	3.20	554,250	1,773,600	1,625,678	Dec 23 04:40 PM

Open in Screener

ADMA

Adma Biologics Inc

Jan 17 • 04:00PM ET

16.02

Dollar change -0.61
Percentage change -3.67	%

Healthcare • Biotechnology • USA • NASD

ADMA Adma Biologics Inc daily Stock Chart

Peers: CSL GRFS BAX BMY PFE JNJ MRK LLY COHR GILD

| Held by: IJR VTI IWM XBI VXF IJT SPSM IWO IBB SLYG

Index	RUT	P/E	57.98	EPS (ttm)	0.28	Insider Own	3.34%	Shs Outstand	236.38M	Perf Week	-13.69%
Market Cap	3.79B	Forward P/E	23.44	EPS next Y	0.68	Insider Trans	-10.44%	Shs Float	228.50M	Perf Month	-15.60%
Income	68.13M	PEG	2.76	EPS next Q	0.15	Inst Own	87.24%	Short Float	5.96%	Perf Quarter	-2.55%
Sales	382.81M	P/S	9.89	EPS this Y	489.74%	Inst Trans	14.98%	Short Ratio	4.51	Perf Half Y	22.76%
Book/sh	0.98	P/B	16.33	EPS next Y	34.87%	ROA	18.42%	Short Interest	13.62M	Perf Year	224.95%
Cash/sh	0.37	P/C	43.67	EPS next 5Y	21.00%	ROE	35.55%	52W Range	4.82 - 23.64	Perf YTD	-6.59%
Dividend Est.	-	P/FCF	47.70	EPS past 5Y	38.68%	ROI	19.92%	52W High	-32.23%	Beta	0.76
Dividend TTM	-	Quick Ratio	3.26	Sales past 5Y	73.38%	Gross Margin	48.79%	52W Low	232.37%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	7.09	EPS Y/Y TTM	369.01%	Oper. Margin	30.01%	RSI (14)	35.94	Volatility	6.05% 4.89%
Employees	624	Debt/Eq	0.48	Sales Y/Y TTM	63.39%	Profit Margin	17.80%	Recom	1.00	Target Price	26.00
Option/Short	Yes / Yes	LT Debt/Eq	0.48	EPS Q/Q	1233.64%	Payout	-	Rel Volume	1.01	Prev Close	16.63
Sales Surprise	13.25%	EPS Surprise	25.38%	Sales Q/Q	78.13%	Earnings	Nov 07 AMC	Avg Volume	3.02M	Price	16.02
SMA20	-8.78%	SMA50	-16.36%	SMA200	10.18%	Trades		Volume	3,052,861	Change	-3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-23	Resumed	Raymond James	Strong Buy	$5
Oct-13-22	Initiated	Mizuho	Buy	$5
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy	$5
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jun-04-19	Initiated	Jefferies	Buy	$8
Apr-15-19	Reiterated	H.C. Wainwright	Buy	$10 → $13
Feb-07-19	Resumed	H.C. Wainwright	Buy	$10
Dec-11-17	Reiterated	Maxim Group	Buy	$13 → $8
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy	$13
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy	$24 → $14
May-13-15	Reiterated	Maxim Group	Buy	$18 → $24
Dec-08-14	Initiated	Oppenheimer	Outperform	$20
Dec-01-14	Reiterated	Maxim Group	Buy	$16 → $18

Show Previous Ratings

Jan-14-25 05:50PM	Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why (Zacks)
Jan-13-25 07:00AM	ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update (GlobeNewswire) -11.15%
Jan-11-25 10:00AM	The Top Stock Funds of 2024 (The Wall Street Journal)
Jan-09-25 04:53PM	Is ADMA Biologics, Inc. (ADMA) the Best Growth Stock to Buy Now Under $25? (Insider Monkey)
Jan-08-25 05:50PM	Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
02:54PM	Loading…
02:54PM	SpringWorks Therapeutics Stock Gets A RS Rating Lift (Investor's Business Daily)
09:30AM	Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? (Zacks)
Jan-07-25 07:00AM	ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025 (GlobeNewswire)
Jan-01-25 12:39PM	Why Is ADMA Biologics, Inc. (ADMA) Among the Best Multibagger Stocks to Buy Right Now? (Insider Monkey)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-20-24 07:00AM	ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility (GlobeNewswire)
Dec-11-24 03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
Dec-04-24 09:55AM	Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-02-24 02:16PM	Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Nov-27-24 09:40AM	Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? (Zacks)
09:51AM	Loading…
Nov-26-24 09:51AM	Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge (Investor's Business Daily)
Nov-18-24 09:55AM	Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High? (Zacks)
Nov-15-24 09:30AM	Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet (Zacks) -5.74%
Nov-12-24 09:15AM	ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily)
Nov-08-24 12:19PM	Q3 2024 ADMA Biologics Inc Earnings Call (Thomson Reuters StreetEvents) +14.71%
06:37AM	ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA) (GlobeNewswire)
02:28AM	ADMA Biologics Inc (ADMA) Q3 2024 Earnings Call Highlights: Record Revenue and Net Income Surge (GuruFocus.com)
Nov-07-24 07:20PM	Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates (Zacks)
06:17PM	Adma Biologics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 07:08AM	ADMA Biologics Inc (ADMA) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 02:34PM	Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock? (Zacks)
Nov-01-24 04:08PM	ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle (Investor's Business Daily) +18.76%
Oct-30-24 09:30AM	Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? (Zacks)
05:50PM	Loading…
Oct-29-24 05:50PM	Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
04:10PM	ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-21-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm (GlobeNewswire)
05:50PM	Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Oct-17-24 01:01PM	State Street Corp's Strategic Acquisition of ADMA Biologics Shares (GuruFocus.com)
Oct-15-24 05:50PM	Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note (Zacks)
Oct-14-24 09:30AM	Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? (Zacks)
Oct-11-24 09:21AM	ADMA Biologics Has Nearly Quadrupled As It Changes The 'Bubble Boy' Narrative (Investor's Business Daily)
Oct-10-24 04:55PM	Nasdaq Cuts Losses, But Indexes Stay In The Red; Fortinet Triggers New Buy Point, Palo Alto Networks Approaches Breakout Entry (Live Coverage) (Investor's Business Daily) -16.31%
04:07PM	IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns (Investor's Business Daily)
11:13AM	How ADMA Biologics Is Changing The 'Bubble Boy' Narrative And Dominating The IBD 50 (Investor's Business Daily)
Oct-09-24 05:54PM	ADMA Biologics Inc (ADMA) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com)
05:50PM	Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts (Zacks)
Oct-02-24 05:50PM	Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why (Zacks)
09:40AM	Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? (Zacks)
Sep-30-24 08:50AM	Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Sep-27-24 03:53PM	Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia (Investor's Business Daily)
Sep-26-24 07:27PM	Is ADMA Biologics Inc. (ADMA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
05:50PM	Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why (Zacks)
Sep-23-24 07:07PM	Millennium Management LLC Acquires Shares in ADMA Biologics Inc (GuruFocus.com)
Sep-20-24 05:50PM	Adma Biologics (ADMA) Gains As Market Dips: What You Should Know (Zacks)
Sep-17-24 07:00AM	ADMA Biologics Set to Join S&P SmallCap 600 Index (GlobeNewswire)
Sep-10-24 09:35AM	Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average (Zacks) -5.93%
09:15AM	ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue? (Zacks)
07:00AM	ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 06:43PM	Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) +13.04%
Aug-29-24 09:40AM	Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year? (Zacks)
09:30AM	Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Aug-19-24 11:40AM	ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow? (Zacks)
Aug-14-24 08:59AM	ADMA Biologics Announces Partial Paydown of Revolving Credit Facility (GlobeNewswire)
Aug-13-24 09:30AM	Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet (Zacks)
09:15AM	ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-12-24 08:50AM	Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Aug-08-24 09:56PM	ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +6.46% +30.93%
06:10PM	Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:04PM	Adma Biologics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 07:00AM	ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-31-24 05:45PM	Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know (Zacks)
Jul-30-24 05:50PM	Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Jul-25-24 08:50AM	Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why (Zacks)
Jul-24-24 05:50PM	Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know (Zacks)
Jul-22-24 10:31AM	What's in Store for ADMA Biologics (ADMA) in Q2 Earnings? (Zacks)
Jul-18-24 05:50PM	Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors (Zacks)
Jul-13-24 09:00AM	3 Millionaire-Making Stock Picks With Astounding Growth Potential (InvestorPlace)
Jul-11-24 09:43AM	Bull Run Alert: 3 Stocks Set to Soar in the Coming Months (InvestorPlace)
Jul-09-24 09:40AM	Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:50AM	Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-08-24 05:50PM	Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
09:05AM	Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options (Zacks)
Jun-27-24 09:30AM	Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? (Zacks)
Jun-26-24 05:50PM	Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jun-20-24 05:50PM	Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jun-11-24 09:30AM	Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? (Zacks)
May-13-24 09:40AM	Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? (Zacks)
May-10-24 02:26PM	ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript (Insider Monkey) +27.13%
01:25PM	ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024 (GuruFocus.com)
10:57AM	Update: ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance (MT Newswires)
04:06AM	ADMA Biologics Swings to Q1 Earnings, Revenue Rises; Lifts 2024 Guidance (MT Newswires)
May-09-24 06:20PM	Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
05:17PM	Adma Biologics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-02-24 05:45PM	Adma Biologics (ADMA) Rises Higher Than Market: Key Facts (Zacks)
07:00AM	ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-30-24 09:30AM	Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Apr-29-24 11:26AM	What's in Store for ADMA Biologics (ADMA) in Q1 Earnings? (Zacks)
Apr-25-24 05:45PM	Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know (Zacks)
Apr-24-24 08:50AM	Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why (Zacks)
Apr-19-24 05:45PM	Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note (Zacks)
Apr-17-24 05:50PM	Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELMS STEVE	Director	Nov 27 '24	Option Exercise	10.80	9,000	97,200	2,124,671	Dec 02 09:02 PM
Tade Brad L.	CFO and Treasurer	Nov 22 '24	Sale	21.15	15,000	317,250	199,433	Nov 22 09:05 PM
Grossman Adam S	President and CEO	Nov 22 '24	Sale	21.10	48,967	1,033,204	1,989,007	Nov 22 09:05 PM
Grossman Adam S	Director and Officer	Nov 22 '24	Proposed Sale	21.30	48,967	1,042,997		Nov 22 09:00 PM
Tade Brad L.	Officer	Nov 22 '24	Proposed Sale	21.30	15,000	319,500		Nov 22 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Option Exercise	10.80	9,000	97,200	162,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Sale	18.47	9,000	166,189	153,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Proposed Sale	16.26	9,000	146,340		Sep 09 09:00 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Aug 30 '24	Option Exercise	3.87	24,150	93,526	473,238	Aug 30 09:05 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Aug 30 '24	Sale	16.90	24,150	408,050	449,088	Aug 30 09:05 PM
Grossman Jerrold B	Director	Aug 29 '24	Option Exercise	4.28	136,861	585,871	604,166	Aug 30 09:02 PM
Grossman Jerrold B	Director	Aug 29 '24	Sale	17.27	136,861	2,363,932	467,305	Aug 30 09:02 PM
Kestenberg-Messina Kaitlin M.	Officer	Aug 30 '24	Proposed Sale	17.22	24,150	415,863		Aug 30 09:00 PM
Grossman Jerrold B	Director	Aug 29 '24	Proposed Sale	17.24	136,861	2,359,484		Aug 29 09:26 PM
Grossman Adam S	President and CEO	Aug 26 '24	Option Exercise	6.84	236,889	1,619,466	2,296,615	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 27 '24	Option Exercise	3.30	389,356	1,283,725	2,449,082	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 27 '24	Sale	17.29	389,356	6,732,900	2,059,726	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 26 '24	Sale	17.69	236,889	4,191,088	2,059,726	Aug 27 09:22 PM
KWON YOUNG	Director	Aug 23 '24	Sale	18.26	60,000	1,095,600	241,441	Aug 27 09:00 PM
Grossman Adam S	Officer	Aug 26 '24	Proposed Sale	18.20	626,245	11,397,659		Aug 26 09:28 PM
Grossman Adam S	President,CEO, and Interim CFO	Jun 14 '24	Sale	10.72	100,000	1,071,980	2,081,475	Jun 14 09:00 PM
ELMS STEVE	Director	Mar 19 '24	Sale	6.08	411,829	2,503,920	2,115,671	Mar 19 09:48 PM
ELMS STEVE	Director	Mar 18 '24	Sale	6.01	49,887	299,821	2,527,500	Mar 19 09:48 PM
ELMS STEVE	Director	Mar 14 '24	Sale	6.05	448,276	2,712,070	2,760,395	Mar 15 09:00 PM
ELMS STEVE	Director	Mar 13 '24	Sale	6.21	407,000	2,527,470	3,208,671	Mar 15 09:00 PM
ELMS STEVE	Director	Mar 15 '24	Sale	6.01	183,008	1,099,878	2,577,387	Mar 15 09:00 PM

MRKR

Marker Therapeutics Inc

ADMA

Adma Biologics Inc

Upgrade your FINVIZ experience